# Live LLM Analyst Execution Transcripts

**Execution Date:** 2026-10-17 20:27:38 UTC
**Endpoint:** `https://api.groq.com/openai/v1`
**Model ID:** `openai/gpt-oss-120b`
**Protocol:** Model Context Protocol (MCP) Stdio Client (`mcp.client.session.ClientSession`)
**Temperature:** `0` | **Max Steps:** `6`
**Fallback Status:** None (All runs autonomous model-selected tools)

---

## Question 1: "what should we do first?"

### Run 1
- **Execution Mode:** `model-selected tools`
- **Duration:** 5.82s
- **Tools Chosen (3):** `blast_radius`, `rank_guidelines`, `open_ticket`
- **Algorithms Triggered:** `algo.pageRank`

#### Execution Trace

| Step | Tool | Arguments | Output Summary | Selected By |
|---|---|---|---|---|
| 1 | `blast_radius` | `{"retraction_id": "SYN-RET-001"}` | {'retraction_id': 'SYN-RET-001', 'affected_trials': ['SYN-TR-0001'], 'affected_reviews': ['SYN-REV-001'], 'affected_guidelines': ['SYN-GL-001'], 'at_risk_decisi | `model-selected tools` |
| 2 | `rank_guidelines` | `{}` | {'algorithm': 'algo.pageRank', 'top_guidelines': [{'id': 'SYN-GL-001', 'title': 'Clinical Practice Guideline on Cardiology Protocol 1 (SYN)', 'score': 0.0193},  | `model-selected tools` |
| 3 | `open_ticket` | `{"assignee_group": "Clinical Evidence Review Committee", "description": "The retraction of trial SYN\u2011TR\u20110001 propagates to systematic review SYN\u2011REV\u2011001, guideline SYN\u2011GL\u2011001, and at\u2011risk decisions DEC\u2011CARDIO\u2011002, DEC\u2011CARDIO\u2011001, DEC\u2011GEN\u2011011. Initiate committee review, recompute pooled effects, and assess guideline updates.", "priority": "high", "title": "Remediation of at\u2011risk decisions due to retraction SYN\u2011RET\u2011001", "decision_id": "DEC-CARDIO-001"}` | {'status': 'created', 'ticket_id': 'TCK-MCP-7fc687f4', 'decision_id': 'DEC-CARDIO-001', 'title': 'Remediation of at‑risk decisions due to retraction SYN‑RET‑001 | `model-selected tools` |

#### Final Model Response

```
**First‑step actions**

1. **Blast‑radius assessment** – The retraction **SYN‑RET‑001** impacts:
   * Trial **SYN‑TR‑0001**
   * Systematic review **SYN‑REV‑001**
   * Guideline **SYN‑GL‑001**
   * At‑risk institutional decisions:
     * **DEC‑CARDIO‑002** – Target LDL Threshold Standard for Post‑Infarction Care (Cardiology Steering Committee)
     * **DEC‑CARDIO‑001** – Hospital‑wide Formulary Adoption of Triple‑Antiplatelet Protocol (Cardiology Steering Committee)
     * **DEC‑GEN‑011** – Clinical Operational Protocol #11 (Oncology Formulary Steering Committee)

2. **Guideline criticality ranking** – PageRank shows **SYN‑GL‑001** (Cardiology Protocol 1) as the highest‑scoring guideline (score 0.0193) among those linked to the retraction, indicating it is the most influential guideline to review first.

3. **Ticket creation** – A remediation ticket has been opened (Ticket **TCK‑MCP‑7fc687f4**, priority **high**) addressed to the **Clinical Evidence Review Committee**. The ticket requests:
   * Immediate committee review of the affected decisions.
   * Re‑computation of pooled effect estimates for **SYN‑REV‑001** without the retracted trial.
   * Evaluation of updates needed for **SYN‑GL‑001** and any downstream policies.

**Next recommended step**  
The Clinical Evidence Review Committee should convene (via the ticket) to:
* Verify the blast‑radius findings.
* Run a **recompute_pooled_effect** analysis for **SYN‑REV‑001**.
* Draft provisional revisions to **SYN‑GL‑001** and flag the three decisions as *at‑risk* pending committee approval.

All actions should be documented, and any changes to clinical practice must await formal committee endorsement.
```

### Run 2
- **Execution Mode:** `model-selected tools`
- **Duration:** 16.13s
- **Tools Chosen (3):** `blast_radius`, `rank_guidelines`, `open_ticket`
- **Algorithms Triggered:** `algo.pageRank`

#### Execution Trace

| Step | Tool | Arguments | Output Summary | Selected By |
|---|---|---|---|---|
| 1 | `blast_radius` | `{"retraction_id": "SYN-RET-001"}` | {'retraction_id': 'SYN-RET-001', 'affected_trials': ['SYN-TR-0001'], 'affected_reviews': ['SYN-REV-001'], 'affected_guidelines': ['SYN-GL-001'], 'at_risk_decisi | `model-selected tools` |
| 2 | `rank_guidelines` | `{}` | {'algorithm': 'algo.pageRank', 'top_guidelines': [{'id': 'SYN-GL-001', 'title': 'Clinical Practice Guideline on Cardiology Protocol 1 (SYN)', 'score': 0.0192},  | `model-selected tools` |
| 3 | `open_ticket` | `{"affected_nodes": ["SYN-TR-0001", "SYN-REV-001", "SYN-GL-001", "DEC-CARDIO-002", "DEC-CARDIO-001", "DEC-GEN-011"], "description": "Retraction of trial SYN-TR-0001 propagates to systematic review SYN-REV-001, guideline SYN-GL-001, and at\u2011risk decisions DEC-CARDIO-002, DEC-CARDIO-001, DEC-GEN-011. Initiate review, re\u2011analysis, and communication with committees.", "priority": "high", "retraction_id": "SYN-RET-001", "title": "Remediation for Retraction SYN-RET-001 Impact", "decision_id": "DEC-CARDIO-001"}` | {'status': 'created', 'ticket_id': 'TCK-MCP-8e2e8a0f', 'decision_id': 'DEC-CARDIO-001', 'title': 'Remediation for Retraction SYN-RET-001 Impact'} | `model-selected tools` |

#### Final Model Response

```
**First‑step remediation plan**

1. **Blast‑radius assessment** – The retraction of trial **SYN‑TR‑0001** propagates through:
   * Systematic review **SYN‑REV‑001**
   * Clinical guideline **SYN‑GL‑001**
   * At‑risk institutional decisions:
     * **DEC‑CARDIO‑002** – “Target LDL Threshold Standard for Post‑Infarction Care” (Cardiology Steering Committee)
     * **DEC‑CARDIO‑001** – “Hospital‑wide Formulary Adoption of Triple‑Antiplatelet Protocol” (Cardiology Steering Committee)
     * **DEC‑GEN‑011** – “Clinical Operational Protocol Decision #11 (SYN)” (Oncology Formulary Steering Committee)

2. **Guideline criticality ranking** – PageRank analysis shows **SYN‑GL‑001** (Cardiology Protocol 1) has the highest influence score (0.0192) among the impacted guidelines, followed by other SYN‑GL‑00X guidelines.

3. **Ticket creation** – A high‑priority remediation ticket has been opened:
   * **Ticket ID:** **TCK‑MCP‑8e2e8a0f**
   * **Title:** *Remediation for Retraction SYN‑RET‑001 Impact*
   * **Scope:** Affected nodes – SYN‑TR‑0001, SYN‑REV‑001, SYN‑GL‑001, DEC‑CARDIO‑002, DEC‑CARDIO‑001, DEC‑GEN‑011.
   * **Next actions:**  
     - Convene the Cardiology Steering Committee (Dr. Tariq Mansour, Dr. David Thorne, Dr. Priya Patel, Dr. Marcus Vance, Dr. Sarah Chen) and Oncology Formulary Steering Committee (Dr. Chloe Bennett, Dr. Rebecca Kim, Dr. Priya Patel, etc.) for a formal review.  
     - Re‑run systematic‑review meta‑analyses without the retracted trial (using `recompute_pooled_effect`).  
     - Update or temporarily flag the affected guideline **SYN‑GL‑001** pending re‑analysis.  
     - Document findings and decisions in the ticket before any clinical practice changes are made.

**Recommendation:** Proceed with the coordinated committee review and evidence re‑analysis as outlined above. No direct changes to clinical practice should be enacted until the human review process completes and the ticket is resolved.
```

## Question 2: "who knows about Cardiology?"

### Run 1
- **Execution Mode:** `model-selected tools`
- **Duration:** 5.08s
- **Tools Chosen (1):** `who_knows`
- **Algorithms Triggered:** `None`

#### Execution Trace

| Step | Tool | Arguments | Output Summary | Selected By |
|---|---|---|---|---|
| 1 | `who_knows` | `{"topic": "Cardiology"}` | {'topic': 'Cardiology', 'experts': [{'person': 'Dr. Sarah Chen', 'role': 'Chief of Cardiology & Guideline Chair', 'evidence_count': 9}, {'person': 'Dr. Marcus V | `model-selected tools` |

#### Final Model Response

```
**Experts with the highest evidence footprint on Cardiology**

| Person | Role | Evidence Count* |
|--------|------|-----------------|
| Dr. Sarah Chen | Chief of Cardiology & Guideline Chair | 9 |
| Dr. Marcus Vance | Senior Interventional Cardiologist | 7 |
| Dr. Priya Patel | Head of Clinical Pharmacy & Formulary | 1 |
| Dr. David Thorne | Vascular Surgery Section Chief | 1 |

\* Number of distinct trials, systematic reviews, or guideline contributions the individual is linked to in the evidence graph.

These individuals are the primary contacts for any review, remediation, or committee discussion related to cardiology evidence, including the ongoing retraction investigation (SYN‑RET‑001).  

*Next steps (if needed):*  
- Engage Dr. Chen and Dr. Vance for a rapid evidence‑contamination assessment.  
- Open a remediation ticket and flag any at‑risk decisions after confirming the blast radius.  

(Per policy, any changes to clinical practice should be routed through the appropriate institutional review committee.)
```

### Run 2
- **Execution Mode:** `model-selected tools`
- **Duration:** 6.45s
- **Tools Chosen (1):** `who_knows`
- **Algorithms Triggered:** `None`

#### Execution Trace

| Step | Tool | Arguments | Output Summary | Selected By |
|---|---|---|---|---|
| 1 | `who_knows` | `{"topic": "Cardiology"}` | {'topic': 'Cardiology', 'experts': [{'person': 'Dr. Sarah Chen', 'role': 'Chief of Cardiology & Guideline Chair', 'evidence_count': 9}, {'person': 'Dr. Marcus V | `model-selected tools` |

#### Final Model Response

```
**Experts with the highest evidence footprint on Cardiology**

| Person | Role | Evidence Count* |
|--------|------|-----------------|
| Dr. Sarah Chen | Chief of Cardiology & Guideline Chair | 9 |
| Dr. Marcus Vance | Senior Interventional Cardiologist | 7 |
| Dr. Priya Patel | Head of Clinical Pharmacy & Formulary | 1 |
| Dr. David Thorne | Vascular Surgery Section Chief | 1 |

\* Number of distinct trials, systematic reviews, or guideline contributions the individual is linked to in our evidence graph.

These individuals are the primary contacts for any review, remediation, or committee discussion related to cardiology evidence, including the ongoing retraction investigation (SYN‑RET‑001).  

*Next steps (if needed):*  
- Engage the top experts (Dr. Chen and Dr. Vance) for a rapid evidence‑contamination assessment.  
- Open a remediation ticket and flag any at‑risk decisions after confirming the blast radius.  

(Per policy, any changes to clinical practice should be routed through the appropriate institutional review committee.)
```

## Question 3: "which decisions are at risk?"

### Run 1
- **Execution Mode:** `model-selected tools`
- **Duration:** 12.66s
- **Tools Chosen (2):** `blast_radius`, `path_to_decision`
- **Algorithms Triggered:** `algo.SPpaths`

#### Execution Trace

| Step | Tool | Arguments | Output Summary | Selected By |
|---|---|---|---|---|
| 1 | `blast_radius` | `{"retraction_id": "SYN-RET-001"}` | {'retraction_id': 'SYN-RET-001', 'affected_trials': ['SYN-TR-0001'], 'affected_reviews': ['SYN-REV-001'], 'affected_guidelines': ['SYN-GL-001'], 'at_risk_decisi | `model-selected tools` |
| 2 | `path_to_decision` | `{"retraction_id": "SYN-RET-001", "decision_id": "DEC-CARDIO-001"}` | {'source': 'SYN-RET-001', 'target': 'DEC-CARDIO-001', 'path_found': True, 'algorithm': 'algo.SPpaths', 'path_nodes': ['SYN-RET-001', 'SYN-TR-0001', 'SYN-REV-001 | `model-selected tools` |

#### Final Model Response

```
**Decisions currently flagged as “at‑risk” by the blast‑radius analysis of retraction SYN‑RET‑001**

| Decision ID | Decision Title | Evidence Path (retraction → trial → review → decision) |
|-------------|----------------|--------------------------------------------------------|
| **DEC‑CARDIO‑002** | Target LDL Threshold Standard for Post‑Infarction Care | SYN‑RET‑001 → **SYN‑TR‑0001** → **SYN‑REV‑001** → DEC‑CARDIO‑002 |
| **DEC‑CARDIO‑001** | Hospital‑wide Formulary Adoption of Triple‑Antiplatelet Protocol | SYN‑RET‑001 → **SYN‑TR‑0001** → **SYN‑REV‑001** → **DEC‑CARDIO‑001** (path confirmed by `path_to_decision`) |
| **DEC‑GEN‑011** | Clinical Operational Protocol Decision #11 (SYN) | SYN‑RET‑001 → **SYN‑TR‑0001** → **SYN‑REV‑001** → DEC‑GEN‑011 |

**Sources**

* **Blast‑radius output** – lists the three at‑risk decisions (DEC‑CARDIO‑002, DEC‑CARDIO‑001, DEC‑GEN‑011) and the review that connects them (SYN‑REV‑001)【blast_radius】.  
* **Shortest‑path to decision** – confirms the concrete graph path from the retraction to DEC‑CARDIO‑001 via trial SYN‑TR‑0001 and review SYN‑REV‑001【path_to_decision】.

---

### Next steps (recommended for the Evidence Governance Committee)

1. **Flag each decision** in the knowledge graph as `at_risk` (using `flag_decision`).  
2. **Open remediation tickets** for the responsible committees (Cardiology Steering Committee, Oncology Formulary Steering Committee) so that a formal human review can be scheduled.  
3. **Schedule a committee review** to reassess the underlying evidence, recompute pooled effect sizes if needed, and determine whether the decisions should be revised, paused, or upheld.

*No direct changes to clinical practice are recommended here; the appropriate human oversight bodies should evaluate the impact before any policy alteration.*
```

### Run 2
- **Execution Mode:** `model-selected tools`
- **Duration:** 19.82s
- **Tools Chosen (2):** `blast_radius`, `path_to_decision`
- **Algorithms Triggered:** `algo.SPpaths`

#### Execution Trace

| Step | Tool | Arguments | Output Summary | Selected By |
|---|---|---|---|---|
| 1 | `blast_radius` | `{"retraction_id": "SYN-RET-001"}` | {'retraction_id': 'SYN-RET-001', 'affected_trials': ['SYN-TR-0001'], 'affected_reviews': ['SYN-REV-001'], 'affected_guidelines': ['SYN-GL-001'], 'at_risk_decisi | `model-selected tools` |
| 2 | `path_to_decision` | `{"retraction_id": "SYN-RET-001", "decision_id": "DEC-CARDIO-001"}` | {'source': 'SYN-RET-001', 'target': 'DEC-CARDIO-001', 'path_found': True, 'algorithm': 'algo.SPpaths', 'path_nodes': ['SYN-RET-001', 'SYN-TR-0001', 'SYN-REV-001 | `model-selected tools` |

#### Final Model Response

```
**Decisions currently flagged as “at‑risk” by the blast‑radius analysis for retraction SYN‑RET‑001**

| Decision ID | Decision Title | Evidence Path (key nodes) | Responsible Committee |
|-------------|----------------|---------------------------|------------------------|
| **DEC‑CARDIO‑002** | Target LDL Threshold Standard for Post‑Infarction Care | SYN‑RET‑001 → **SYN‑TR‑0001** → **SYN‑REV‑001** → DEC‑CARDIO‑002 | Cardiology Steering Committee |
| **DEC‑CARDIO‑001** | Hospital‑wide Formulary Adoption of Triple‑Antiplatelet Protocol | SYN‑RET‑001 → **SYN‑TR‑0001** → **SYN‑REV‑001** → **DEC‑CARDIO‑001** (shortest‑path confirmed) | Cardiology Steering Committee |
| **DEC‑GEN‑011** | Clinical Operational Protocol Decision #11 (SYN) | SYN‑RET‑001 → **SYN‑TR‑0001** → **SYN‑REV‑001** → DEC‑GEN‑011 | Oncology Formulary Steering Committee |

*Source data* – The blast‑radius query returned the three decision nodes above (DEC‑CARDIO‑002, DEC‑CARDIO‑001, DEC‑GEN‑011) together with the underlying trial (**SYN‑TR‑0001**) and systematic review (**SYN‑REV‑001**) that incorporate the retracted data【blast_radius】.  
The shortest‑path algorithm also confirmed a direct evidence chain from the retraction to **DEC‑CARDIO‑001** (SYN‑RET‑001 → SYN‑TR‑0001 → SYN‑REV‑001 → DEC‑CARDIO‑001)【path_to_decision】.

---

### Next steps (human‑driven)

1. **Flag each decision** in the institutional knowledge graph as *at‑risk* (using the `flag_decision` tool) so that they appear in the oversight dashboards.  
2. **Open remediation tickets** for the responsible committees (e.g., Cardiology Steering Committee, Oncology Formulary Steering Committee) to trigger a formal review of the underlying evidence and any downstream clinical recommendations.  
3. ** convene a multidisciplinary evidence‑review panel** (including members listed in the “notify” fields of the blast‑radius output) to reassess the affected guidelines and determine whether any interim practice advisories are needed.  

*No direct changes to clinical practice should be enacted until the designated committees complete their review.*
```

